跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

Kyowa Kirin Pharmaceutical Development Ltd.

首页临床试验发起方与机构Kyowa Kirin Pharmaceutical Development Ltd.

Kyowa Kirin Pharmaceutical Development Ltd.

ACTIVE

英国www.kyowakirin.comSubsidiary

隶属于 KYOWA KIRIN INTERNATIONAL PLC

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

23

10 进行中

药物批准

0

批准总数

监管机构

0

监管机构数

成立时间

N/A

概览

试验阶段分布

阶段

试验数

占比

1 期

15

65.2%

3 期

1

4.3%

试验状态分布

进行中（未招募）

10

43.5%

已完成

9

39.1%

招募中

1

4.3%

终止

1

4.3%

撤回

2

8.7%

相关临床试验

该机构主办的试验（23）

Real World Observational Study of Poteligeo in Adult Patients With MF and SS (PROSPER)

Nov 202273 名受试者

A Study to Describe the Lived Experience of XLH for Adolescents at End of Skeletal Growth

Nov 202125 名受试者

A UK Multicentre, Health-Related Quality of Life Study for Children and Adolescents With XLH

Apr 202132 名受试者

Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age

Feb 202016 名受试者

A Phase 1/2, Open-label, Multicenter, Non-randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Pediatric Patients from Birth to Less than 1 Year of Age with X-linked Hypophosphatemia (XLH)

进行中（未招募）

Nov 201920 名受试者

A Phase 1/2, Study to measure the safety, tolerability and the action of drugs in the body (method and rate of excretion; duration of effect on the body) and effectivity of Burosumab in children from birth to less than 1 year of age with inheritable form of rickets

进行中（未招募）

Oct 201920 名受试者

A Phase 1/2, Open-label, Multicenter, Non-randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Pediatric Patients from Birth to Less than 1 Year of Age with X-linked Hypophosphatemia (XLH)

进行中（未招募）

Oct 201920 名受试者

A Phase 1/2, Study to measure the safety, tolerability and the action of drugs in the body (method and rate of excretion; duration of effect on the body) and effectivity of Burosumab in children from birth to less than 1 year of age with inheritable form of rickets

进行中（未招募）

Oct 201920 名受试者

第 1 页，共 3 页

药物批准

暂无批准数据

资讯

暂无资讯文章

本页目录

概览
相关临床试验23
药物批准
资讯

返回机构列表